Navigation Links
Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
Date:8/27/2009

potential, decreasing exacerbations and improving lung function. The uniformity of the results is really encouraging and gives us great hope that our faith in roflumilast has been confirmed. We are now undergoing the regulatory review process with the European and US authorities."

"Based on the results from the pivotal studies published this week, it appears that roflumilast provides added activity on top of other commonly used treatments for COPD," said Lawrence S. Olanoff, President and Chief Operating Officer of Forest Laboratories. "Roflumilast represents the first in a new class of agents to treat COPD and, if approved, would be the first oral anti-inflammatory maintenance treatment for the disease."

About Roflumilast (Daxas(R))

Roflumilast( )is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor targeting cells and mediators in the body believed to be important in the COPD disease process. Roflumilast is expected to act on the underlying mechanism of COPD and related inflammatory diseases. If approved, roflumilast, a once-a-day oral tablet, will be the first in an entirely new class of treatment for COPD. It will also be the first oral anti-inflammatory treatment for COPD patients. Current treatment for COPD patients includes the use of inhaled bronchodilators and inhaled corticosteroids.

About COPD

COPD is an under-diagnosed progressive lung disease that may lead to death. Worldwide, COPD kills four people every minute and the World Health Organization (WHO) predicts that it will be the third leading cause of death by 2030. WHO estimates that 80 million people have moderate to severe COPD.

Symptoms of COPD include breathlessness, chronic cough and excessive production of phlegm. A significant worsening of symptoms called an exacerbation or lung attack can last several weeks. Breathing becomes severely compromised and patients may need to be admitted to
'/>"/>

SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
3. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
4. PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
5. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. School of Dentistry Studies Link Between Oral Health and Memory
8. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
9. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ), ... to MDBX.  The company previously announced that their name ... The company is a leader in the design, manufacture ... The free-standing unit features 60 or more slots that ...
... 2011 This year, the melanoma community saw the first ... This major step forward will give more than 400 party-goers ... Gala.  They will gather at the Trump National Golf Club ... these cutting-edge advances and raise money for future research through ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 3
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... International Cancer Research team has come out with the startling ... development of tumors in mice. This discovery could be vital ... molecules work by blocking the hormones that are essential for ... they strangle the tumor by blocking blood and nutrient supply ...
... turning their backs on tanning amid growing concerns over skin ... survey shows that teenagers are resisting the urge to tan ... 5,073 Australian adults and 699 Australian teenagers aged 12 to ... that 68 % of those aged 12-17 said they had ...
... part of the school curriculum from Class IX in all ... the age of 25. The new curriculum would be made ... the Human Resource Department of Government of India and National ... ministry has also made it compulsory to train teachers on ...
... have reacted with skepticism to a British man's claims that he ... some relief. // , ,In what is assumed as a ... now available in India. , ,This medicine is provided in ... that it would help the infected people to lead a much ...
... are unconcerned with the effect of their habit on the ... the damage // that smoking caused to the tongue or ... strangely reluctant to change their habits. This is of particular ... a massive awareness campaign as a part of the Mouth ...
... a doctor's permission is good at any time of life, ... study. // ,Thomas Foster and other scientists from the McKnight ... of rats that had lived to old age. Some were ... , ,Scientists examined chemical compounds in 41 tissue samples ...
Cached Medicine News:Health News:Aussie teens applauded for declining sun tan 2Health News:Regular light exercise slows down aging of the brain 2
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Barr periosteal elevators....
Seldin periosteal elevators....
Williger periosteal elevators....
Medicine Products: